Piqray® (alpelisib) – New drug approval
May 24, 2019 - The FDA announced the approval of Novartis’ Piqray (alpelisib) in combination with Faslodex® (fulvestrant) for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Top